UBS AM’s KalVista Pharmaceuticals KALV Stock Holding History

UBS AM’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,743	Closed	-$699K	–	3810
2026 Q1	$699K	Buy	34,743 +7,021	+25%	+$113K	﹤0.01%	2460
2025 Q4	$448K	Buy	27,722 +14,122	+104%	+$187K	﹤0.01%	2345
2025 Q3	$166K	Buy	+13,600	New	+$188K	﹤0.01%	2228

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS AM's KALV Position: Q2 2026 in Review

UBS AM sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 34,743 shares — an estimated $699K sold.

UBS AM first reported a position in KALV in Q3 2025 and held it in 3 quarters. The position peaked at $699K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

UBS AM reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
UBS AM sold 34,743 KalVista Pharmaceuticals shares in Q2 2026, an estimated $699K.
UBS AM first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 3 quarters.
UBS AM's KalVista Pharmaceuticals position peaked at $699K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.